Phathom Pharmaceuticals (PHAT) Competitors $11.84 -0.22 (-1.82%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$11.84 0.00 (0.00%) As of 09/12/2025 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PHAT vs. ZLAB, CRNX, KYMR, RARE, TLX, NAMS, VKTX, XENE, AMRX, and SRRKShould you be buying Phathom Pharmaceuticals stock or one of its competitors? The main competitors of Phathom Pharmaceuticals include Zai Lab (ZLAB), Crinetics Pharmaceuticals (CRNX), Kymera Therapeutics (KYMR), Ultragenyx Pharmaceutical (RARE), Telix Pharmaceuticals (TLX), NewAmsterdam Pharma (NAMS), Viking Therapeutics (VKTX), Xenon Pharmaceuticals (XENE), AMNEAL PHARMACEUTICALS (AMRX), and Scholar Rock (SRRK). These companies are all part of the "pharmaceutical products" industry. Phathom Pharmaceuticals vs. Its Competitors Zai Lab Crinetics Pharmaceuticals Kymera Therapeutics Ultragenyx Pharmaceutical Telix Pharmaceuticals NewAmsterdam Pharma Viking Therapeutics Xenon Pharmaceuticals AMNEAL PHARMACEUTICALS Scholar Rock Zai Lab (NASDAQ:ZLAB) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, media sentiment, valuation and risk. Is ZLAB or PHAT more profitable? Zai Lab has a net margin of -49.68% compared to Phathom Pharmaceuticals' net margin of -289.51%. Phathom Pharmaceuticals' return on equity of 0.00% beat Zai Lab's return on equity.Company Net Margins Return on Equity Return on Assets Zai Lab-49.68% -27.32% -18.85% Phathom Pharmaceuticals -289.51%N/A -90.40% Which has more risk and volatility, ZLAB or PHAT? Zai Lab has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Comparatively, Phathom Pharmaceuticals has a beta of 0.44, indicating that its stock price is 56% less volatile than the S&P 500. Does the media favor ZLAB or PHAT? In the previous week, Zai Lab had 9 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 13 mentions for Zai Lab and 4 mentions for Phathom Pharmaceuticals. Phathom Pharmaceuticals' average media sentiment score of 0.98 beat Zai Lab's score of 0.69 indicating that Phathom Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zai Lab 4 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Phathom Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend ZLAB or PHAT? Zai Lab presently has a consensus target price of $56.35, indicating a potential upside of 71.80%. Phathom Pharmaceuticals has a consensus target price of $17.50, indicating a potential upside of 47.80%. Given Zai Lab's higher possible upside, research analysts clearly believe Zai Lab is more favorable than Phathom Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zai Lab 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86Phathom Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has better valuation and earnings, ZLAB or PHAT? Zai Lab has higher revenue and earnings than Phathom Pharmaceuticals. Zai Lab is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZai Lab$398.99M9.19-$257.10M-$2.04-16.08Phathom Pharmaceuticals$114.04M7.37-$334.33M-$4.73-2.50 Do institutionals and insiders believe in ZLAB or PHAT? 41.7% of Zai Lab shares are held by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are held by institutional investors. 5.0% of Zai Lab shares are held by company insiders. Comparatively, 23.0% of Phathom Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. SummaryZai Lab beats Phathom Pharmaceuticals on 10 of the 17 factors compared between the two stocks. Get Phathom Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PHAT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PHAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHAT vs. The Competition Export to ExcelMetricPhathom PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$855.59M$3.20B$5.87B$10.13BDividend YieldN/A2.30%5.68%4.60%P/E Ratio-2.5021.1774.5225.93Price / Sales7.37437.97517.44183.79Price / CashN/A46.6837.5660.44Price / Book-3.199.6112.166.29Net Income-$334.33M-$53.29M$3.28B$270.77M7 Day Performance-4.05%0.28%0.87%3.88%1 Month Performance13.15%5.73%4.96%4.88%1 Year Performance-35.30%10.52%60.75%26.01% Phathom Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHATPhathom Pharmaceuticals2.4034 of 5 stars$11.84-1.8%$17.50+47.8%-39.3%$855.59M$114.04M-2.50110Positive NewsZLABZai Lab3.0331 of 5 stars$31.33+1.9%$56.35+79.9%+59.1%$3.44B$398.99M-15.361,869Positive NewsInsider TradeHigh Trading VolumeCRNXCrinetics Pharmaceuticals3.6874 of 5 stars$35.14-1.3%$68.86+96.0%-33.6%$3.35B$1.04M-8.55210Positive NewsKYMRKymera Therapeutics2.6658 of 5 stars$43.26-0.6%$58.76+35.8%+5.1%$3.11B$47.07M-12.47170Positive NewsRAREUltragenyx Pharmaceutical4.4734 of 5 stars$31.51-1.0%$81.50+158.6%-47.6%$3.07B$560.23M-5.701,294Positive NewsAnalyst ForecastTLXTelix Pharmaceuticals3.6374 of 5 stars$9.05-0.1%$22.33+146.8%N/A$3.07B$516.72M0.00N/ANews CoverageAnalyst ForecastGap DownNAMSNewAmsterdam Pharma3.4851 of 5 stars$25.09-7.1%$41.55+65.6%+51.2%$3.04B$45.56M-15.494News CoveragePositive NewsInsider TradeHigh Trading VolumeVKTXViking Therapeutics4.2757 of 5 stars$25.48-5.6%$86.92+241.1%-60.5%$3.03BN/A-16.6520Positive NewsXENEXenon Pharmaceuticals2.3787 of 5 stars$38.19-2.6%$53.30+39.6%-8.0%$3.02B$9.43M-10.76210Positive NewsAMRXAMNEAL PHARMACEUTICALS2.7338 of 5 stars$9.73+1.1%$11.60+19.2%+18.1%$3.02B$2.79B973.978,100News CoveragePositive NewsSRRKScholar Rock4.4879 of 5 stars$31.58+0.5%$45.75+44.9%+283.4%$3.02B$33.19M-10.85140News CoveragePositive News Related Companies and Tools Related Companies Zai Lab Alternatives Crinetics Pharmaceuticals Alternatives Kymera Therapeutics Alternatives Ultragenyx Pharmaceutical Alternatives Telix Pharmaceuticals Alternatives NewAmsterdam Pharma Alternatives Viking Therapeutics Alternatives Xenon Pharmaceuticals Alternatives AMNEAL PHARMACEUTICALS Alternatives Scholar Rock Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PHAT) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phathom Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Phathom Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PHAT Stock Alerts